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Abstract
Background: Tensin2 deficiency results in alterations in podocytes and subsequent glomerular and
tubulointerstitial injuries. However, this pathology is critically dependent on genetic background. While the
Tensin2-deficient podocytes of resistant murine strains, including C57BL/6J mice, remain almost intact, susceptible
murine strains with Tensin2 deficency, including ICGN mice, develop chronic kidney disease following alterations in
the podocyte foot processes. In a previous study, genome-wide linkage analysis was utilized to identify the
quantitative trait loci associated with the disease phenotypes on mouse chromosome 2. This study investigated the
disease phenotypes of chromosome 2 consomic and subcongenic strains.
Results: ICGN consomic mice introgressed with chromosome 2 from the C57BL/6J mouse were generated and found
to exhibit milder renal failure than that in ICGN mice. We developed 6 subcongenic strains that carry C57BL/6J-derived
chromosomal segments from the consomic strain. One showed significantly milder albuminuria, another showed
significantly milder tubulointerstitial injury, and the both showed significantly milder glomerular injury.
Conclusions: These data indicate that mouse chromosome 2 harbors two major genes associated with the severities
of nephropathy induced by Tensin2 deficiency. The proximal region on chromosome 2 contributes to the resistance to
tubulointerstitial fibrosis. In contrast, the distal region on chromosome 2 contributes to the resistance to podocyte
injury. This study would be helpful to discover the biological mechanism underlying the renal injury, and may lead to
the identification of therapeutic targets.
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Background
Chronic kidney disease (CKD) is a public-health problem
characterized by either kidney damage or a long-term de-
cline in kidney function regardless of disease type or
cause, and is becoming increasingly common in both de-
veloped and developing countries across the globe [1]. Pa-
tients with CKD are at high risk for developing end-stage
renal disease (ESRD), requiring costly renal replacement
therapy or renal transplantation [1]. In addition, CKD is
strongly linked to important diseases such as diabetes,
hypertension and cardiovascular disease [2]. Faced with
these outcomes, clinical research efforts over the last few
decades have focused on preventing or delaying the
progression of CKD. Unfortunately, no fundamental ther-
apy is available at present [3].
Taking into account both renal structure and its role in
the continuous filtration of blood flow, we can easily im-
agine that renal glomerular damage due to abnormal blood
pressure or components is a potential risk factor for CKD
progression. Proteinuria is intimately involved in the dys-
function of glomerular visceral epithelial cells (podocytes)
or their intercellular junctions (slit diaphragms), and
glomerulosclerosis sequentially starts with a decreased
podocyte count (podocytopenia). Glomerulosclerosis is one
of the most common histopathological findings of CKD,
and mutations in a number of podocyte-specific genes re-
sponsible for glomerulosclerosis have been identified in
humans [4]. Therefore, podocyte injury is a common deter-
mining factor for progression toward many types of kidney
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disease that result in CKD [5]. Nevertheless, the molecular
mechanisms underlying CKD progression remain unclear.
The onset, progression and severity of CKD can be
strongly influenced by genetic background. For example,
ESRD incidence rates are higher in blacks, Asians and
Hispanics in comparison with whites [6]. These racial
disparities indicate the presence of modifier genes that
prevent or accelerate the progression of CKD. Elucidating
the reasons for these differences among diverse genetic
backgrounds could help in unraveling the mechanisms for
the progression of CKD as well as in developing novel
therapies for it, regardless of predisposing factors.
This study approaches CKD with the abovementioned
aim in mind, using ICGN mice, a spontaneous CKD
mouse model. The null mutation in the tensin2 gene
(Tns2) is known to be the major causative factor for
renal failure in ICGN mice [7], although the function of
Tns2 in the kidney and the mechanism by which Tns2
deficiency leads to renal failure remain unknown. Tns2
is a multidomain protein that possesses C1, PTPase,
SH2 and PTB domains, and is considered to mediate
integrin-associated signaling cascades and regulate Akt
signaling [8–11]. Despite its ubiquitous expression and
predicted function, Tns2 deficiency results only in alter-
ations in podocytes and subsequent glomerular and tubu-
lointerstitial injuries [7, 12–14]. In addition, the severity of
the renal failure caused by Tns2 deficiency is strongly in-
fluenced by murine genetic background [11, 14–16]. This
genetic background-dependent diversity indicates the
presence of modifier genes that prevent renal failure in-
duced by Tns2 deficiency. Recently, we performed a quan-
titative trait loci (QTL) analysis using backcross progenies
from susceptible ICGN and resistant C57BL/6J (B6) strain
mice, and identified significant loci for CKD progression
on chromosome (Chr) 2 in Tns2-deficient mice [17]. In
the present study, to verify the existence of the CKD-
resistant loci on Chr 2 from the B6 mouse, we produced
ICGN consomic mice homozygously introgressed with
Chr 2 from the B6 mouse for the evaluation of CKD
progression.
Methods
Animals
B6 female mice (Charles River Laboratories Japan, Tokyo,
Japan) were backcrossed to ICGN male mice, and conso-
mic ICGN-Chr 2B6 mice were generated by repeated
marker-assisted backcrossing. The 115 genetic markers
used for the Chr substitution between ICGN and B6 mice
are shown in Additional file 1: Table S1. The congenic
ICGN.B6-Tns2WT (ICGN-Tns2WT) mice were generated
by backcrossing the wild-type Tns2 from B6 mice into an
ICGN background for 10 generations. Genotyping of the
Tns2nph allele (accession MGI:2447990) on Chr 15 was
performed as previously described [17]. In order to
determine the effect of each QTL on Chr 2, backcrossing
of ICGN-Chr 2B6 mice to ICGN mice was repeated several
times, with six subcongenic strains eventually produced
by a marker-assisted speed congenic strategy: ICGN.B6-
(D2Mit1-D2Mit64) (referred to as ICB2-1), ICGN.B6-
(D2Mit64-D2Mit369) (ICB2-2), ICGN.B6-(rs49812762-
D2Mit328) (ICB2-3), ICGN.B6-(D2Mit378-D2Mit328)
(ICB2-4), ICGN.B6-(D2Mit219-D2Mit102) (ICB2-5) and
ICGN.B6-(D2Mit102-D2Mit451) (ICB2-6) strains. All
strains were born in accordance with Mendelian inherit-
ance at an equal sex ratio. The additional genetic markers
for fine mapping of introgressed genomic intervals of the
six subcongenic strains are shown in Fig. 4 and Additional
file 1: Table S2. The map positions of the microsatellite
markers were based on information from the Mouse Gen-
ome Informatics of the Jackson Laboratory (MGI; http://
www.informatics.jax.org/, MGI_4.41). The animal facility
was air-conditioned at 22 ± 2 °C, maintained at 40–60 %
relative humidity, and mice were maintained under a 12 h
light-dark cycle. A standard laboratory diet, Labo MR
Standard (Nosan, Kanagawa, Japan), and tap water were
provided ad libitum. The animals’ microbiological status
was monitored periodically according to Japanese Associ-
ation of Laboratory Animal Facilities of Public and Private
Universities guidelines. A humane end point was applied
when the mice with severe anemia became moribund.
Male virgin mice were used for all analyses.
Measurements of blood
Blood samples from 16-week-old mice were collected
from the inferior vena cava under 4 % isoflurane
anesthesia. Hemoglobin concentration (Hb), hematocrit
(Ht), red blood cell count (RBC) and blood urea nitro-
gen (BUN) were measured using an automated counter
(KX-21NV; Sysmex Corporation, Kobe, Japan) and an
automated biochemical analyzer (Dri-Chem 7000; Fuji
Photo Film, Tokyo, Japan) as described previously [15].
Measurement of urinary albumin excretion
Urine samples were collected by gentle manual com-
pression of the abdomen at 4, 8, 16 and 28 weeks of age.
A 10-μL aliquot (containing 2 % sodium dodecyl sulfate
(SDS), 5 % β-mercaptoethanol, 10 % glycerol, 60 mM
Tris-HCl (pH 6.8), bromophenol blue and 1 μL of urine)
was heated for 5 min at 95 °C and applied to 10 % SDS-
polyacrylamide gel electrophoresis. As a positive control,
5 μg of bovine serum albumin was loaded simultan-
eously. The gel was fixed and stained with Coomassie
brilliant blue (CBB; Wako, Osaka, Japan) according to
manufacturer’s instructions, and scanned by a standard
commercial scanner. CBB-stained urinary albumin was
quantified by the gel analysis program of ImageJ (http://
imagej.net/).
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Histological damage scores
Formalin-fixed and paraffin-embedded kidney blocks
were sectioned at a thickness of 2 μm, and stained with
periodic acid-Schiff (PAS) solution. The severity of renal
damage was quantitated using two types of histopatho-
logical score (a glomerular index and tubular index) as
previously described [14, 17]. The glomerular index,
based on the progression of glomerulosclerosis, was cal-
culated as an average of the following ratings for 20 ran-
domly selected glomeruli: 0, no abnormality; 1, mild
expansion of the mesangial matrix; 2, partial thickening
of glomerular basement membrane (GBM); 3, vascular
stenoses (partial expansion of the mesangial matrix); 4,
entire expansion of the mesangial matrix; and 5, abnor-
mal dilation of capillary lumen or retraction and collapse
of the glomerular tuft [14]. To provide a more precise
definition of the progression of tubulointerstitial fibrosis,
we modified the previously described tubular index. The
modified tubular index is the sum of the following ob-
servations: 1, mild tubular dilations or 2, focal tubular
dilations or 3, massive tubular dilations; 1, huge dilation
(>200 μm) of the tubules with urinary casts; 1, interstitial
cell expansion or 2, severe interstitial cell expansion
(Additional file 1: Figure S1). Zero points signify the ab-
sence of any abnormality. The mice were analyzed at
16 weeks of age as ICGN mice show severe albuminuria
and anemia, which are the end stages of a variety of
pathological conditions.
Evaluation of tubulointerstitial fibrosis
Formalin-fixed and paraffin-embedded kidney blocks
were sectioned at a thickness of 3 μm, and processed for
Masson’s trichrome (MT) staining. Five random renal
cortex fields for each sample were chosen, and the anil-
ine blue (AB)-stained area, representing interstitial colla-
gen spread, was measured using ImageJ software.
Immunohistochemical analysis
Kidneys from 16-week-old mice were fixed with 10 %
buffered formalin at 4 °C overnight. The formalin-fixed
paraffin sections (2-μm thick) were subjected to normal
histological processes and antigen retrieval with citrate
buffer (pH 6.0). After treatment with 3 % H2O2 and block-
ing with normal donkey serum for 1 h, sections were incu-
bated with goat anti-mouse IL-1F6 antibody (1:400
diluted, R&D Systems, Minneapolis, MN, USA) at 4 °C
overnight. Sections were then incubated with biotin-
conjugated donkey anti-goat IgG secondary antibody
(Santa Cruz Biotechnology, Dallas, TX, USA) for 30 min
at room temperature, and treated with horseradish
peroxidase-conjugated streptavidin complex (Histofine;
Nichirei Biosciences, Tokyo, Japan) for 3,3-diaminobenzi-
dine (DAB) staining. Five random renal cortex fields for
each sample were chosen, and the signal intensity of DAB
was measured using ImageJ software.
Ultrastructural analysis
Kidneys from 16-week-old mice were cut into small
pieces (1 mm3) and prefixed in 2.5 % buffered glutaral-
dehyde for 4 h, and then fixed with 1 % buffered
osmium tetroxide for 2 h. Fixed tissues were dehydrated
by graded alcohol, and embedded in epoxy resin (Quetol
812 Mixture; Nisshin EM, Tokyo, Japan). Epoxy resin-
embedded specimens were sectioned at a thickness of
70 nm, stained with uranyl acetate and lead citrate, and
observed under a JEOL transmission electron micro-
scope (JEM-1210; JEOL, Tokyo, Japan).
Statistics
Data are expressed as means ± standard deviation. Statis-
tical analyses were performed with Student’s t-test,
Mann-Whitney U test, Dunnett’s multiple comparison
test and Dunn’s multiple comparison test. P <0.05 was
considered significant.
Results
Verification of CKD-resistant loci on chromosome 2
For verification of the existence of the CKD-resistant loci
on Chr 2 from the B6 mice, which are linked to all tested
parameters for CKD, we produced ICGN consomic mice
homozygously introgressed with Chr 2 (D2Mit1-D2Mit229,
2.23–88.99 cM) from the B6 mouse (ICGN-Chr 2B6) using
marker-assisted backcrossing. For phenotype analyses of
the ICGN-Chr 2B6 mice, we produced a congenic mouse
possessing an ICGN genetic background by replacing
Tns2nph with wild-type Tns2 (ICGN-Tns2WT) as a control
strain not affected by nephropathy. The ICGN, ICGN-Chr
2B6 and ICGN-Tns2WT phenotypes were then analyzed.
ICGN mice showed low Hb (11.3 ± 0.9 mg/dL) and low Ht
(38.2 ± 2.8 %) (Fig. 1a). On the other hand, the erythrocytic
parameters of the ICGN-Chr 2B6 mice as well as those of
the ICGN-Tns2WT were at normal levels (Hb, 14.3 ±
1.0 mg/dL; Ht, 49.1 ± 4.6, Fig. 1a). There was no significant
difference in BUN between the ICGN and ICGN-Chr 2B6
mice, with no ICGN-Chr 2B6 mice and only a few ICGN
mice showing an abnormal BUN level (Fig. 1a). Both ICGN
and ICGN-Chr 2B6 mice developed albuminuria by 8 weeks
of age, but the urinary albumin excretion in ICGN-Chr 2B6
mice was always lower than that in ICGN mice (4.8 ±
1.1 μg/μL vs. 18.1 ± 2.7 μg/μL at 16 weeks old, Fig. 1b).
Histopathologic analysis of the kidney sections revealed
that ICGN-Chr 2B6 mice showed a milder phenotype than
did ICGN mice (Figs. 2 and 3). Injury severity scores var-
ied widely in the glomeruli of ICGN-Chr 2B6 mice,
whereas almost all of the glomeruli of ICGN mice showed
entire expansion of the mesangial matrix or collapse of
the glomerular tufts (score 5, also see Fig. 2). Massive
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dilations of the proximal tubules with urinary casts,
interstitial cell expansion and accumulation of interstitial
collagen were observed in ICGN mice, but not in ICGN-
Chr 2B6 mice up to 16 weeks old (Fig. 2 and Additional file
1: Figure S2). These tubulointerstitial lesions were mainly
found in renal cortex. In addition, the ratio of the IL-1 F6-
positive area, a marker of tubulointerstitial lesions [18], in
the renal cortex parenchymal tissue of congenic mice was
less than that for the ICGN mice (1.53 ± 0.22 % vs. 0.30 ±
0.17 %, Additional file 1: Figure S3). Indeed, In ICGN-Chr
2B6 mice, marked injuries as found in 16-week old ICGN
mice were detected up to 28 weeks old, indicating that
ICGN-Chr 2B6 mice developed tubulointerstitial fibrosis
slowly compared with ICGN mice (Fig. 2 and Additional
file 1: Figure S2, S4). Electron microscope observation also
showed that the ultrastructural glomerular alterations in
the ICGN-Chr 2B6 mice were milder than those in the
ICGN mice (Fig. 3).
ICGN-Tns2WT mice did not develop albuminuria up
to 28 weeks old, but unexpectedly, displayed slight foot
process effacement and GBM thickening in a few glom-
eruli (Figs. 1b and 3c). In addition, ICGN-Tns2WT mice
showed noticeable focal tubular dilation without collage-
nous thickening (score 1, Additional file 1: Figure S4).
Genetic mapping for the resistance to the nephropathy
In order to map the CKD-resistant loci on Chr 2 from the
B6 mice, we generated six subcongenic strains that carried
a genomic segment of Chr 2 of B6 mice from ICGN-Chr
2B6. The genomic regions from the B6 mice and their
phenotypic summary are shown in Fig. 4. Among these
subcongenic strains, only ICB2-6 mice and ICGN-Chr 2B6
mice exhibited significantly lower urinary albumin excre-
tion than ICGN mice at 8 weeks of age (Fig. 5). Even at
16 weeks old, urinary albumin excretion in ICB2-6 mice
remained at a low level similar to that in ICGN-Chr 2B6
mice (Figs. 1b and 5). On the other hand, only ICB2-3
mice among these subcongenic strains exhibited a signifi-
cantly lower tubular index than that in ICGN mice (Fig. 5).
Although there were no significant differences in tubular
index between ICGN and the subcongenic strains except
ICB2-3, ICB2-6 mice also showed milder tubulointerstitial
lesions than did ICGN mice (tubular index 1.8 ± 1.2 vs.
3.5 ± 1.1, Fig. 5). With regard to the glomerular index and
Fig. 1 Measurements of blood and urine. a Hematologic parameters at 16 weeks of age. The levels of Hb and Ht in ICGN-Chr 2B6 mice and ICGN-Tns2WT
mice were normal. With regard to BUN, no significant difference was observed between ICGN and ICGN-Chr 2B6 mice, with some ICGN mice but no
ICGN-Chr 2B6 mice showing abnormal BUN levels. b Urinary albumin excretion. Albuminuria was already observed at 4 weeks after birth in ICGN and
ICGN-Chr 2B6 mice. Asterisks indicate P-values for Dunnett’s multiple comparison test, ** <0.01 and * <0.05 vs. ICGN mice (a), or ICGN-Chr 2B6 mice at
the same time point (b) n.s., not significant. Error bars represent standard error. Eleven ICGN mice, four ICGN-Chr 2B6 mice and three ICGN-Tns2WT mice
were analyzed
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Fig. 2 Histological analyses of PAS-stained renal sections from 16-week-old mice. a Representative glomerular and cortical sections. ICGN: entire
expansion of the mesangial matrix and vascular dilations (score 5), massive tubular dilations with urinary casts and cell infiltrations. ICGN-Chr 2B6:
partial expansion of the mesangial matrix and vascular stenoses (score 3). ICGN-Tns2WT: nearly normal (upper, score 0), partial expansion of the
mesangial matrix and vascular wall thickening (lower, score 2). b The mean ratio of the glomerular injury scores each sample. c Glomerular injury
index and tubular injury index. Asterisks indicate P-values for Dunn’s multiple comparison test, ** <0.01 and * <0.05 vs. ICGN mice. Error bars represent
standard error. Eleven ICGN mice, four ICGN-Chr 2B6 mice and three ICGN-Tns2WT mice were analyzed
Fig. 3 Ultrastructure of the glomeruli at 16 weeks of age. In ICGN mice (a), high-level effacement of the podocyte foot processes, high-level thickening
of the GBM and swelling of the podocytes (Pod) were observed. In ICGN-Chr 2B6 mice (b), normal GBM and foot processes (arrow) as well as thickening
of the GBM (asterisk) and effacement of the foot processes (arrowhead) were observed with a much milder phenotype than that of ICGN mice. In
ICGN-Tns2WT mice (c), the glomeruli were nearly normal, but some part of the foot processes and the GBM was abnormal. Cap, capillary
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renal collagenous thickening as assessed by MT staining,
both ICB2-3 and ICB2-6 mice exhibited significantly
milder phenotypes than did ICGN mice (Fig. 5 and
Additional file 1: Figure S2).
Discussion
We previously reported the mapping of genetic loci re-
sponsible for resistance to congenital nephropathy caused
by a Tns2 deficiency in a B6 genetic background. Analysis
of backcrossing between resistant B6 mice and susceptible
ICGN mice has identified significant QTLs on Chrs 2 and
13 [17]. Among the tested traits, tubulointerstitial injury
(tubular index) and anemia (Hb and Ht) were strongly as-
sociated with the same locus on Chr 2, possibly because,
in patients with CKD, anemia develops due to decreased
renal erythropoietin synthesis resulting from tubulointer-
stitial damage [16]. In fact, the ICGN consomic mice car-
rying B6-derived Chr 2 (ICGN- Chr 2B6) exhibited a
milder phenotype than did the ICGN mice, indicating the
existence of a CKD-related locus on Chr 2 (Figs. 1, 2 and
3 and Additional file 1: Figure S2, S3).
Next, we produced six subcongenic strains from ICGN-
Chr 2B6 mice for genetic mapping of the CKD-related locus
on Chr 2. Interestingly, phenotypic analysis of kidney dis-
ease in the subcongenic mice revealed that two strains have
a resistant phenotype (Fig. 4). ICB2-6 mice exhibited lower
urinary albumin excretion, at a level similar to that of
ICGN-Chr 2B6 mice, than did ICGN mice (Fig. 5). ICB2-3
mice as well as ICGN mice developed massive albuminuria,
but ICB2-3 mice exhibited milder tubulointerstitial fibrosis
than did ICGN mice (Fig. 5 and Additional file 1: Figure
S2). These results suggest that two genetic loci on mouse
Chr 2 independently confer resistance to CKD, and
contribute to the ICGN-Chr 2B6 mouse phenotypes; i.e.,
ICB2-6 and ICB2-3 mice show resistance to albuminuria
(i.e., podocyte injury) and tubulointerstitial fibrosis, respect-
ively. The milder glomerular phenotype of ICB2-6 mice is
considered to be due to their resistance to podocyte injury
and subsequent proteinuria and glomerulosclerosis (Fig. 5)
[19]. Tubulointerstitial fibrosis, the final common pathway
of CKD leading to ESRD, is formed via the epithelial-
mesenchymal transition of tubular epithelial cells in a com-
plex cellular and molecular milieu caused by glomerular
proteinuria [20–23]. Tubulointerstitial fibrosis thereby leads
to secondary glomerular injury [24]. These renal patholo-
gies are thought explain why ICB2-6 mice and ICB2-3 mice
exhibited milder histological phenotypes in terms of tubular
and glomerular index, respectively (Fig. 5 and Additional
file 1: Figure S2). In contrast, ICB2-4 and ICB2-5 mice,
which possess a genomic interval from B6 mice that
Fig. 4 Chromosome 2 genotypes and phenotypic summary of the congenic strains. The white and black bars indicate the genomic region from
ICGN and B6 mice, respectively. The shaded bar shows an unclear genomic region in which recombination occurred. If a phenotypic severity was
significantly alleviated by genetic recombination compared to that of ICGN mice (see Fig. 5 and Additional file 1: Figure S2), it is defined as
resistant (R). If not, it is defined as susceptible (S). Tns2nph-induced tubulointerstitial fibrosis related locus, Ttir, is located in rs33151033-D2Mit378
(49.5–68.8 Mb). Tns2nph-induced podocyte injury related locus, Tpir, is located in D2Mit102-D2Mit409 (114.1–158.5 Mb)
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overlaps with the genome of both ICB2-3 and ICB2-6 mice,
did not show a resistant phenotype.
From the results of our congenic line analysis, we
mapped the genomic intervals associated with resistance
to podocyte injury and tubulointerstitial fibrosis in Tns2-
deficiet mice, and designated the former locus Tpir,
Tns2nph-induced podocyte injury resistance, and the latter
locus Ttir, Tns2nph-induced tubulointerstitial fibrosis
resistance (Fig. 4). The region conferring tubulointerstitial
fibrosis resistance, Ttir, covers the LOD peak positions of
QTLs for resistance to tubulointerstitial injury and renal
anemia in Tns2-deficient mice (31 and 36 cM) [17]. As
with many nephropathy model rodents, tubulointerstitial fi-
brosis in ICGN mice is considered to be a secondary lesion
following early podocyte injury [13, 14], thus the resistant
effect on tubulointerstitial fibrosis should potentially work
Fig. 5 Urinary albumin excretion, glomerular index and tubular index of the congenic strains. ICGN-Chr 2B6 and ICGN data are identical to Figs. 1b and 2.
Statistical analysis was performed for ICGN and all subcongenic strains. Dunn’s and Dunnett’s multiple comparison test were used for statistical analyses of
glomerular and tubular injury indexes, and urinary albumin excretion, respectively. Asterisks indicate P-values, *** <0.001, ** <0.01 and * <0.05 vs ICGN mice.
n.s., no significant differences compared with ICGN mice. Error bars represent standard error. Five ICB2-1 mice, three ICB2-2 mice and eight ICB2-3 mice,
two ICB2-4 mice, eight ICB2-5 mice and seven ICB2-6 mice were analyzed
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irrespective of cause. The gene responsible for Ttir is, there-
fore, speculated to help universally block CKD progression
toward ESRD. Similar approaches have been attempted in
human CKD, but the efficacies against renal fibrosis proven
in experimental animal models have not been successfully
demonstrated in human trials [25]. The likely reason for
this is that renal fibrosis in experimental animal models,
such as the unilateral ureteral obstruction (UUO) model
and nephrectomy model, only appears similar to that in hu-
man CKD while being essentially different from it. CKD in
ICGN mice progresses gradually from continuous glomeru-
lar injury to tubulointerstitial fibrosis like human CKD,
while experimental animal models display acute tubuloin-
terstitial fibrosis, which is rather close to patients with acute
kidney injury. Actually, B6 mouse was found to be resistant
to renal fibrosis in bovine serum albumin (BSA)-injected
proteinuria model, but be susceptible to renal fibrosis in
UUO model [26, 27]. From this perspective as well, the
gene responsible for Ttirmay shed light on novel molecular
mechanisms associated with renal fibrosis, although Ttir
does not overlap with previously reported genetic loci asso-
ciated with renal fibrosis or ESRD.
While ICGN-Chr 2B6 mice displayed lower urinary al-
bumin excretion and milder ultrastructural alterations in
podocytes than did ICGN mice (Figs. 1b and 3), the
Tns2-deficient mice possessing the genetic background
of the B6 or 129+Ter/SvJcl (129 T) mice do not even de-
velop albuminuria [11, 15, 16]. Moreover, although B6
congenic mice carrying the Tns2nph mutation exhibit
slight GBM thickening and mild mesangial expansion,
the morphology of the podocytes remains almost intact
up to 40 weeks of age [11]. That is, in terms of the prim-
ordial prevention of podocyte injury induced by Tns2nph,
the effects of the podocyte injury-resistant region, Tpir,
on Chr 2 from the B6 mouse were insufficient in com-
parison with those of the B6 genetic background itself.
This suggests that other loci outside of Chr 2 confer im-
mediate resistance to Tns2 deficiency.
While both B6 and 129T mice are resistant to Tns2 defi-
ciency, B6 mice also exhibit lower albuminuria in hyper-
tension or diabetes model than do 129 strains [28, 29].
Indeed, B6 mice appear to be resistant to various podocyte
injuries caused not only by Tns2 deficiency but also by
hypertension, diabetes, angiotensin II infusion, HIV-
associated nephropathy (HIVAN), albumin overload, renal
ablation or congenital nephron reduction [28–36]. These
findings lead to the hypothesis that the B6 genetic back-
ground possesses a “pan-resistance” to various podocyte
injuries that works through the protection of the podo-
cytes themselves. With regard to HIVAN, Papeta et al. re-
ported that the transcript level of Nphs2, which encodes
podocin, was linked to strain-dependent resistance, and
B6 and 129/SvEv mice displayed 3-fold higher expression
of Nphs2 than did FVB and D2 mice [33]. The abundance
of podocin, a scaffolding molecule for the slit diaphragm,
in B6 podocytes can be interpreted to mean that B6 mice
have “robust” podocyte foot processes that are resistant to
injury. This concept may be applicable to Tpir. It is inter-
esting that Tpir overlaps with the QTLs for age-associated
albuminuria in crosses between B6 and D2 or A/J mice
(Albq5 and Albq1), and the common genomic interval
(129–158 Mb) includes the LOD peak positions of these
QTLs (Additional file 1: Figure S5) [37, 38]. Normal D2
and A/J mice, which don’t carry a marked risk factor for
renal failure, develop mild albuminuria with increasing
age [37, 38], but this age-associated phenotype appears to
be common in human CKD [39, 40]. As for age-
associated albuminuria, the age-related decrease in the
uptake of glomerular filtrate albumin by renal proximal
tubule as well as glomerular damage can contribute to al-
bumin leak [41]. Age-related change of the expression of
megalin and cubilin, major receptors responsible for the
reabsorption of albumin, was found in old rats [41]. How-
ever, neither genes are located in major QTLs, Albq5, Tpir
and Ttir. It is also notable that the distal region of Tpir
(154–157 Mb) includes the syntenic region of human Chr
20q11.22, which is linked to the estimated glomerular fil-
tration ratio (eGFR) [42], and the proximal region of Tpir
includes Ino80 (119 Mb), which has been identified with
single nucleotides polymorphisms associated with eGFR
in European ancestry samples [43], however, Tpir is still
very broad. Therefore, further studies are needed to nar-
row the genomic interval of Tpir, and investigate whether
Tpir contributes to a “pan-resistance” to various podocyte
injuries in B6 genetic background.
On the other hand, we unexpectedly discovered that
ICGN control mice possessing wild-type Tns2 (ICGN-
Tns2WT) displayed slight alterations in the podocyte foot
processes, GBM and focal tubular dilations without
interstitial fibrosis at 16–28 weeks of age (Fig. 3c and
Additional file 1: Figure S4). These findings indicate that
ICGN mice carry a few minor causative factors for ne-
phropathy in addition to Tns2nph.
Conclusions
Our congenic analysis using Tns2-deficient mice demon-
strated the existence of QTLs for CKD resistance mapped
to Chr 2 in our previous study, and identified that the Chr
2 QTLs were comprised of two genetic regions, Tpir and
Ttir, associated with resistance to podocyte injury and
tubulointerstitial fibrosis, respectively. As the resistance to
these conditions appears to have a protective effect on
renal injuries irrespective of the mechanism by which
Tns2-deficiency leads to renal failure, the genes respon-
sible for this resistance can help protect the kidney from
various renal injuries irrespective of cause and aid in the
development of universally effective therapies for CKD.
Further studies are required to understand the exact
Sasaki et al. BMC Genetics  (2016) 17:69 Page 8 of 10
mechanism of the resistance/susceptibility to renal disease
in our strains. Nevertheless, the present study provides a
first step in the identification of novel causative gene(s)
that might lead to the development of treatment strategies
for CKD.
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